Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Hematology/oncology clinics of North America - 1 Feb 2023

Grinshpun Albert, Sandusky Zachary M, Jeselsohn Rinath

Abstract excerpt

The estrogen receptor is a key driver of estrogen receptor-positive breast cancers. Accumulating evidence indicates that the ESR1 ligand-binding domain mutations have an important role in acquired endocrine resistance, mainly to treatment with aromatase inhibitors. The identification, monitoring, and targeting of ESR1 mutations is an evolving field of major interest given the potential of improved outcomes in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Breast Cancer Treatment Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Estrogen and related hormone effects

Share to Estrogen Receptor alpha

Share to Mutation

Share to Receptors, Estrogen

Source

Identifiers

PMID: 36435608
DOI: 10.1016/j.hoc.2022.08.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.PMID 36435608Read ↗

ESR1 activating mutations: From structure to clinical application.Semantic proximity Read ↗

ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.Semantic proximity Read ↗

Estrogen receptor mutations and their role in breast cancer progression.Semantic proximity Read ↗

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.Semantic proximity Read ↗

Molecular characterization of ESR1 variants in breast cancer.Semantic proximity Read ↗

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.Semantic proximity Read ↗

Molecular Characterization of ESR1 Variants in Breast CancerSemantic proximity Read ↗

ESR1 mutations in breast cancerSemantic proximity Read ↗

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.